Goodwin Procter advised Klaviyo, and Sidley Austin advised the underwriters on the offering. Klaviyo, Inc. announced the pricing of its initial public offering of 19,200,000 shares of...
Klaviyo’s $576 Million Initial Public Offering
Cerence’s $190 Million Convertible Senior Notes Offering
Latham & Watkins represented the initial purchasers in the offering. Cerence Inc. (NASDAQ: CRNC) announced the pricing of $190.0 million aggregate principal amount of 1.50% convertible...
Mobileye’s $1.617 Billion Secondary Offering
Davis Polk & Wardwell LLP advised Mobileye Global Inc on the offering, while Sullivan & Cromwell LLP advised the underwriters. Mobileye Global Inc., a leader of the...
EVgo’s $125 Million Public Equity Offering
Freshfields Bruckhaus advised EVgo, and Latham & Watkins advised the underwriters. EVgo Inc. announced the pricing on May 17, 2023 of an underwritten public offering of 29,411,765...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
EngageSmart’s Public Offering
Latham & Watkins advised EngageSmart, Fenwick & West advised the underwriters, Paul Weiss, Kirkland & Ellis LLP, Maples and Calder (Cayman) and Whalen, respectively, advised certain...
Geron Corporation’s $198 Million Upsized Public Offering
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
SkyWater Technology’s $17.25 Million Rights Offering
Goodwin Procter advised Needham & Company on the deal. SkyWater Technology, Inc. announced the offering of its common stock for an aggregate amount of $17.25 million. The...
Recursion Pharmaceuticals’ $150 Million Private Placement
Davis Polk advised the placement agents in the transaction. Recursion Pharmaceuticals executed its $150 million private placement of common stock. Morgan Stanley & Co. LLC acted as the...
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Liquidia’s $50 Million Common Stock Offering
DLA Piper represented Liquidia, while Latham & Watkins represented the underwriters in the offering. Liquidia Corporation, a biopharmaceutical company focused on the development and commercialization of...
Vaxcyte’s $100 Million Shares Offering
Latham & Watkins represented the underwriters in the transaction. Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of...